Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | CLK3 | P49761 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | NME2 | P22392 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134184 | 0.95 | SYK (0.47) | SYKITKFGFR1KDM4EHPGD | |
| Trifluoroacetic Acid SCHEMBL4130490 | 0.87 | SYK (0.43) | SYKITKKDM4EHPGDABCC1 | |
| Trifluoroacetic Acid SCHEMBL4134146 | 0.86 | SYK (0.49) | SYKITKKDM4EHPGDCACNA1B | |
| SCHEMBL4001593 | 0.81 | SYK (0.46) | SYKITKKDM4EHPGDABCC1 | |
| SCHEMBL4121801 | 0.80 | SYK (0.53) | SYKITKKDM4EHPGD | |
| Trifluoroacetic Acid SCHEMBL4130010 | 0.80 | SYK (0.43) | SYKITKFGFR1KDM4EHPGD | |
| SCHEMBL13375137 | 0.80 | SYK (0.49) | SYKITKKDM4EHPGDABCC1 | |
| Trifluoroacetic Acid SCHEMBL4130036 | 0.79 | ITK (0.42) | SYKITKFGFR1KDM4EHPGD | |
| Trifluoroacetic Acid SCHEMBL4138498 | 0.78 | SYK (0.41) | SYKITKFGFR1KDM4EHPGD | |
| SCHEMBL13373932 | 0.78 | SYK (0.66) | SYKITKKDM4EHPGDABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | SYK 392/4885ITK 1817/4885FGFR1 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.